The period for CME/CE credit for this activity has expired.

Diabetes

The Evolving Landscape of Incretin-Based Therapies: Evaluating Recent Data and Its Clinical Applications

INSTRUCTIONS

After completing the CME evaluation, a continuing education certificate will automatically be generated and should be printed or saved to your computer for your records.

Thank you for your participation.


CME/CE Information

The Evolving Landscape of Incretin-Based Therapies: Evaluating Recent Data and Its Clinical Applications

Agenda
 
Welcome and Introduction
John B. Buse, MD, PhD – Program Director

Talk 1
Incretin Hormones and Type 2 Diabetes: Leveraging the Effects of GLP-1
Patricia L. Brubaker, PhD

Talk 2
Incretin-Based Therapies: Clinical Update
John L. Leahy, MD

Talk 3
Incretin-Based Therapies: Applying Evidence and Guidelines in Practice
John B. Buse, MD, PhD

Program Chair

John B. Buse, MD, PhD
Professor of Medicine
Director, Diabetes Care Center
Chief, Division of Endocrinology
Executive Associate Dean for Clinical Research
University of North Carolina School of Medicine
Chapel Hill, North Carolina

Faculty
 
Patricia L. Brubaker, PhD
Professor and Canada Research Chair
Departments of Physiology and Medicine
Associate Chair, Department of Physiology
University of Toronto
Toronto, Ontario, Canada

John L. Leahy, MD
Professor of Medicine and Chief,
Endocrinology, Diabetes and Metabolism Unit
University of Vermont College of Medicine
Burlington, Vermont

Activity Overview

Type 2 diabetes is a progressive disease that often requires treatment intensification using several therapeutic agents. Incretin-based therapies address numerous pathophysiologic defects in type 2 diabetes with limited side effects. In addition, data are emerging on potential nonglycemic actions of these agents, which may impact future treatment decisions. This content will discuss incretin-based therapies in depth, from pathophysiologic effects to clinical use, and will incorporate interactive questions whereby you can evaluate your answers against those of your colleagues, along with a concluding faculty panel discussion. The most cutting-edge information available on these therapeutic agents will be highlighted, since they continue to be a valuable focus for reshaping type 2 diabetes treatment.

Target Audience
This activity should be of substantial interest to endocrinologists and other healthcare professionals who treat patients with type 2 diabetes.

Learning Format
This activity will feature lectures with interactive questions through interactive online polling, whereby you can evaluate your answers against those of your colleagues.  The program will conclude with a facilitated faculty panel discussion.

Learner Objectives
Upon completion of this educational activity, participants will be able to:

  • Cite the novel aspects of GLP-1 as they relate to the multifactorial nature of type 2 diabetes
  • Evaluate recent evidence regarding glycemic and nonglycemic benefits of incretin-based therapies relative to potential improvement in patient outcomes
  • Compare and contrast the safety and efficacy of GLP-1 agonists and DPP-4 inhibitors
  • Discuss the relevance of incretin-based therapies in the treatment algorithm for type 2 diabetes
  • Describe practical considerations for use of incretin-based therapies for optimal patient management of type 2 diabetes

Accreditation Statement   
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Endocrine Society has achieved Accreditation with Commendation.

The Endocrine Society designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.

Statement of Independence
As a provider of continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, The Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of The Endocrine Society’s Special Programs Committee (SPC). The commercial supporters of this activity have no influence over the selection of the faculty or specific presentations.

Disclaimer
The information presented in this activity represents the opinions of the faculty and is not necessarily the official position of The Endocrine Society.

Disclosure Policy
The faculty, committee members, and staff involved in planning this CME activity are required to disclose to learners any relevant financial relationship(s) that have occurred within the last 12 months with any commercial interest(s) whose products or services are discussed in the CME content. Such relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (eg, stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speaker bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent faculty with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments. It remains for learners to determine whether financial interests or relationships may influence the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationships:

Dr Buse has received indirect benefit, through funds paid to accounts under the control of the University of North Carolina School of Medicine’s Division of Endocrinology, for his services as an investigator, consultant, and/or speaker, from the following companies: Amylin Pharmaceuticals; Bayhill Therapeutics; BD Research Laboratories; Bristol-Myers Squibb; Dexcom; Eli Lilly and Company; GlaxoSmithKline; Hoffman-La Roche; InteKrin Therapeutics; Intuity Medical, Inc; Johnson & Johnson; MannKind Corporation; Medtronic, Inc; Merck & Co, Inc; MicroIslet Inc; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc; Osiris Therapeutics, Inc.; Pfizer Inc; sanofi-aventis; Transition Therapeutics Inc and Wyeth Pharmaceuticals. He also disclosed that he is a shareholder of Insulet Corporation.

Dr Brubaker has received consulting fees from Bristol-Myers Squibb; Forest Laboratories, Inc; Johnson & Johnson and Dr. Reddy’s Laboratories Ltd. She has received speaker honoraria from Bristol-Myers Squibb and Johnson & Johnson.

Dr Leahy has received consulting fees from Novo Nordisk Inc and Daiichi Sankyo Co, Ltd; and has received speaker honoraria from sanofi-aventis and Merck & Co, Inc.

The following SPC members who planned and/or reviewed content for this activity reported no relevant financial relationships:
Mark W. True, MD

The Endocrine Society staff associated with the development of this program reported no relevant financial relationships and/or conflicts of interest.

IMNE staff associated with the development of this program reported no relevant financial relationships and/or conflicts of interest, with the exception of the following:

Kim McFarland, PhD
Senior Medical Writer, IMNE
Freelance Writer: MediTech Media, Ltd (USA)
Stock Interests: Pfizer Inc; Procter & Gamble

Policy on Unlabeled/Off-Label Use
The Endocrine Society has determined that disclosure of unlabeled/
off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation.

Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

Privacy and Confidentiality Statement
The Endocrine Society will record learners’ personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

Acknowledgment of Commercial Support
This activity is supported by an educational grant from
Novo Nordisk Inc.

Method of Participation
To obtain CME credit, each participant should:

  • View the content presented
  • Answer all questions posed throughout the activity
  • Complete and submit the CME demographic and evaluation form
  • Print the online CME certificate

This activity should take approximately 2.0 hours to complete. The expiration date for this activity is December 31, 2010. No credit will be granted after this date.

Minimum System Requirements
The following system requirements are recommended for the best presentation viewing experience:

  • Microsoft Windows 2000, Windows XP, Windows 2003, Windows Vista, or Macintosh OS X
  • Display resolution of 800 x 600 pixels or greater
  • Windows-compatible sound card
  • Microsoft Internet Explorer 6.0 SP1.
  • Windows Media Player 9.0
  • Broadband Internet connection (256 Kbps & above)


For a complete list of system requirements needed to view the webcast please click here (this link opens a pdf document). If you have any questions about viewing the webcast please contact us.

Date of Original Release: Friday, October 9, 2009 (satellite symposium)
Date of Last Review: October 10, 2009
Release Date: December 2009
Expiration Date: December 31, 2010

Estimated Time to Complete this Activity: 2.0 hours

Faculty Bios:

Patricia L. Brubaker, PhD
Professor and Canada Research Chair
Departments of Physiology and Medicine
Associate Chair, Department of Physiology
University of Toronto
Toronto, Ontario, Canada

Dr Brubaker obtained her PhD at McGill University in Montreal in 1982, and joined the University of Toronto as an assistant professor in 1985. She is currently a professor in the Departments of Physiology and Medicine at the University of Toronto. She has been actively involved in diabetes research since 1982, and has lectured nationally and internationally about her research to both scientific and general audiences. Dr Brubaker has received several awards for her diabetes research, including 2 Juvenile Diabetes Foundation International (JDFI) Fellowships (1982 and 1984), a JDFI Career Development Award (1985-1987), and a Diabetes Canada Scholarship (1987-1992). She was also the recipient of the Canadian Diabetes Association (CDA) Young Scientist Award in 1998, and has been supported by generous research grants from the Canadian Institutes of Health Research and the CDA throughout her career.

Dr Brubaker has trained over 30 graduate students and fellows in various aspects of pancreatic and gastrointestinal endocrinology, and has published over 140 papers in high-quality peer-reviewed journals and books. She is recognized for her research into the mechanisms regulating the synthesis, secretion, and biological activities of the intestinal glucagon-like peptides, most notably glucagon-like peptide-1 and -2. In addition, she is currently the recipient of a Tier 1 Canada Research Chair in Vascular and Metabolic Biology from the Government of Canada.

John B. Buse, MD, PhD
Professor of Medicine
Director, Diabetes Care Center
Chief, Division of Endocrinology
Executive Associate Dean for Clinical Research
University of North Carolina School of Medicine
Chapel Hill, North Carolina

Dr Buse received his medical degree and PhD from Duke University in Durham, North Carolina, before training in internal medicine and endocrinology at the University of Chicago. He is currently a professor of medicine at the University of North Carolina School of Medicine (UNC) in Chapel Hill, where he serves as the Director of the Diabetes Care Center, Chief of the Division of Endocrinology, and Executive Associate Dean for Clinical Research.

Dr Buse runs a diabetes practice at UNC and also at the Salem Center for Diabetes Management & Education in Winston-Salem, North Carolina. His research interests focus on developing prevention and treatment strategies for type 1 and 2 diabetes and their complications. Dr Buse is also involved in numerous multicenter clinical trials, most prominently the National Heart, Lung, and Blood Institute’s Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, for which he serves as study vice-chair, and the National Institute of Diabetes and Digestive and Kidney Diseases’ Studies to Treat or Prevent Pediatric Type 2 Diabetes (STOPP-T2D). He serves on the Data Safety Monitoring Board or Steering Committee for the National Institutes of Health and several well-known international studies. He is also active in a number of national teaching efforts focusing on graduate as well as continuing medical education.

Dr Buse just completed service as president for Medicine and Science at the American Diabetes Association and is a board member of the Carolinas Affiliate of the American Association of Clinical Endocrinologists. He has authored more than 200 publications and received numerous awards and honors, including citation in the online resource Best Doctors in America since 2001. 

John L. Leahy, MD
Professor of Medicine and Chief,
Endocrinology, Diabetes and Metabolism Unit
University of Vermont College of Medicine
Burlington, Vermont

Dr Leahy is a professor of medicine and chief of the Endocrinology, Diabetes and Metabolism Unit at the University of Vermont College of Medicine. He received his medical degree in 1977 from the Medical College of Virginia in Richmond. Dr Leahy currently serves as the principal investigator for several National Institutes of Health–funded grants examining β-cell compensation and failure. He has received several awards and honors for his teaching and research in the area of endocrinology, and delivered the Dr Manuel Paniagua Memorial Lecture for the Sociedad Puertorriqueña de Endocrinologia y Diabetologia in 2006. Dr Leahy has authored over 60 publications and 16 book chapters in the area of diabetes and has served as editor for several publications. He is currently co-editor for Diabetes, Year Book of Endocrinology

Dr Leahy is active in many professional endocrinology organizations, serving on the Advisory Panel for the American Diabetes Association’s (ADA’s) Insulin Therapy Initiative (2002-2003), as well as the Planning Committee for the ADA’s Annual Meeting (2004-2005). Currently, he is a member of the ADA, American Association for the Advancement of Science, American Federation for Clinical Research, European Association for the Study of Diabetes, and The Endocrine Society. 


 

 I have read and understand the CME Information indexed above.

Webcast

You must be a registered member of WebBasedCME.com to view this content. Members please sign in. New to WebBasedCME.com? Click here to register.

Members Sign In Below

You must be a registered member of WebBasedCME.com to view this content.






Retrieve Username   Reset Password   Register Here

CME Evaluation

    •  
    • CME Evaluation - This portion of the activity allows us to evaluate the types of healthcare professionals who are participating in the activity. This information will also be used to develop needs assessments for future educational programs on this topic. Thus, to the best of your ability, please respond with what you feel is the most accurate answer.
    •  
    • You can click on each section to preview this activity but you must be signed in to participate and receive CME credit. New to WebBasedCME.com? Click here to register.